@daltonventure
以生命科学为根，向硬科技生长
Dalton Venture launched Shanghai's first bio-manufacturing industry fund, injecting strong patient capital into the sector.
Existing shareholder Dalton Venture continued to increase its stake.
An **AIR incubated company and Tongtou Family portfolio company**, **Shuimu Molecular** has emerged as one of the most promising benchmark enterprises in AI-driven drug discovery, pursuing a dual-engine strategy of "tool empowerment + proprietary pipeline development." Its core achievements include the ChatDD intelligent agent framework, the OpenBioMed open-source platform, Shuimu Zhiliao — a new consumer-facing "super brain" tool for life sciences — and multimodal large models.
Leveraging a Hong Kong-based fund, DoTown deepens its cross-border innovation strategy bridging mainland China and the Greater Bay Area
Dedicated to becoming a leading benchmark in China's domestic wound closure space.
Minhang District Media Center has launched the "**Go, to the Lab**" series, going behind the scenes at Minhang's frontline research facilities to explore breakthrough technologies. This installment visits **a DaoTong portfolio company — KoSyne NeuroTech**.
Sets New Record for Largest Angel Round in China's Brain-Computer Interface Space
Recently, emerging neuromodulation company **MicroVention Medical Technology (Shanghai) Co., Ltd.** (abbreviated as "MicroVention Medical") announced the completion of a tens-of-millions-of-yuan angel funding round. The round was **exclusively invested by Dalton Venture**, marking the company's first external financing since its establishment in 2024.
Recently, **KoSyne NeuroTech** (hereinafter referred to as "KoSyne NeuroTech"), a **Dongtou Family company** specializing in non-invasive brain-computer interfaces and neuromodulation, announced the completion of its **Pre-A funding round** — another key milestone following Dongtou Capital's exclusive angel round investment. **This round was led exclusively by Yunqi Capital, with the proceeds to be used primarily for core technology R&D, clinical translation, and global expansion.**
It leverages cutting-edge synthetic-biology innovations to push everyday products like cosmetics toward safer, more sustainable formulations.
